Compare GTE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTE | TRDA |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.7M | 254.7M |
| IPO Year | 2007 | 2021 |
| Metric | GTE | TRDA |
|---|---|---|
| Price | $8.22 | $6.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 338.3K | ★ 637.9K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $374,460,000.00 | $25,421,000.00 |
| Revenue This Year | $1.39 | $39.97 |
| Revenue Next Year | $2.84 | $50.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 41.99 | N/A |
| 52 Week Low | $3.09 | $4.93 |
| 52 Week High | $9.74 | $16.45 |
| Indicator | GTE | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 32.16 |
| Support Level | $7.30 | $5.58 |
| Resistance Level | $9.69 | $6.90 |
| Average True Range (ATR) | 0.48 | 0.75 |
| MACD | -0.14 | -0.19 |
| Stochastic Oscillator | 6.54 | 7.12 |
Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. The majority of its revenue comes from operations in Colombia.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.